

19 July 2023

## Melodiol delivers strong start to Q3 CY2023 with \$1.6m in new revenue and confirmed POs

### Highlights:

- **\$1.6m of new unaudited revenue and confirmed POs achieved in Q3 CY2023 as of 17 July 2023**
- **Strong trend builds on record breaking Q2 CY2023 revenues of A\$4.7m which were up 105% up on Q1 CY2023**
- **CY2023 sales to date of \$8.6m approaching entire CY2022 record revenues of \$8.7m**
- **Growth underpinned by strong contributions from Mernova Medicinal Inc, Health House International, and Creso Pharma Switzerland**

**Melodiol Global Health Limited (ASX:MEI, FRA:1X8) ('Melodiol' or 'the Company')** is pleased to advise that as of 17 July 2023 it has delivered \$1.6m in new revenue and confirmed POs during Q3 CY2023, which has laid a solid foundation for the Company to continue its current growth trajectory.

The strong start to the September quarter follows record revenue during Q2 CY2023 of \$4.74m, which marked a 105% increase on Q1 CY2023 (refer ASX announcement: 13 July 2023). New sales during Q3 CY2023 takes total unaudited revenue to date for the year to A\$8.6m – approximately equal to record breaking revenues of A\$8.7m for the entire of CY2022.

Q3 CY2023 revenue has been primarily underpinned by Melodiol's two 100%-owned subsidiaries, specialist medicinal cannabis distributor Health House International ('HHI') and Mernova Medicinal Inc. ('Mernova'), a leading supplier of recreational cannabis products in the Canadian market, as well as strong contributions from Creso Pharma Switzerland.

The pleasing start to Q3 CY2023 highlights Melodiol's ongoing focus of consolidating its market momentum following the successful integration of HHI, and driving further growth in revenue and EBITDA across its core operating divisions.

**Chief Executive Officer Mr William Lay said:** *"In recent months, Melodiol has undertaken a number of steps to optimise its operations to capitalise on revenue growth opportunities. The group achieved exceptional momentum during the last quarter and we are pleased to see this continue in the early stages of Q3 FY2023."*

*"The Board and management team are actively assessing a number of opportunities which have the potential to unlock additional value for shareholders and we look forward to providing ongoing operational updates over the coming months."*

**-Ends-**

### **Authority and Contact Details**

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

### **For further information, please contact:**

#### **Investor Enquiries**

Melodiol Global Health Limited  
E: [info@melodiol-global-health.com](mailto:info@melodiol-global-health.com)  
P: +61 (0) 497 571 532

### **About Melodiol**

Melodiol Global Health Limited (ASX:MEI) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

**To learn more please visit:** <https://melodiolglobalhealth.com/>

### **Melodiol offices:**

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Switzerland:** Allmendstrasse 11, 6310 Steinhausen, Schweiz

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.